Ideaya Biosciences has a long-tailed pipeline, strong data from multiple programs, and a huge cash balance. Click here to ...

Fostamatinib was approved in 2018 to treat adults with chronic immune thrombocytopenia (ITP) who had an insufficient response ...

Entertainers like Taylor Swift know the power of an opening act to engage an audience and create a warm welcome for the star performer.

Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) after Short Eight Week ...

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia ...

an NS5A inhibitor, for treatment of hepatitis C virus met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment. Primary endpoint results demonstrated a 98% SVR12 ...

Recent advances in immunotherapy research have revealed crucial roles for new immune cells in combating cancer, leading to ...

A study from the University of Michigan Health Rogel Cancer Center may have, at last, cracked the cold case of immunotherapy resistance.

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas was host to the Bladder Cancer Course and the session Metastatic Urothelial Cancer. Dr. Vadim S. Koshkin ...

In conclusion, by identifying PEBP1 as an amplifier of mitochondrial stress signals, our study provides new insights into cytoplasmic mechanisms which ensure appropriate responses to acute ...

A recent study in Nature Materials introduces an inhalable nanozyme treatment for viral pneumonia, showing promising results ...

At ESMO 2024, Dr. Andrea Necchi presented the results of an interim analysis of SunRISe-4, noting a pathological complete response rate in the combination arm of 42% and pathologic objective response ...